Ph II CHOP+Velcade in Mediastinal LBCL

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

May 31, 2008

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

bortezomib

Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles

DRUG

Rituximab

Given intravenously on day 1 of a 21-day cycle for 6 cycles

DRUG

Cyclophosphamide

Given intravenously on day 1 of a 21-day cycle for 6 cycles

DRUG

Doxorubicin

Given intravenously on day 1 of a 21-day cycle for 6 cycles

DRUG

Vincristine

Given intravenously on day 1 of a 21-day cycle for 6 cycles

DRUG

Prednisone

Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles

RADIATION

Radiation therapy

After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER